What is US Biologic?
US Biologic operates at the intersection of pharmaceutical innovation and public health, specializing in the development of advanced oral vaccine delivery systems. By focusing on scalable solutions for pandemic prevention and the management of zoonotic threats, such as tick-borne illnesses, the company has carved out a distinct niche in the life sciences market. Their technological framework is designed to enhance the efficacy and accessibility of immunization, serving a broad spectrum of stakeholders ranging from agricultural enterprises to global health organizations. As a key player in the biotech ecosystem, US Biologic leverages its research-driven approach to combat emerging pathogens, positioning itself as a critical infrastructure provider for long-term disease prevention strategies.
How much funding has US Biologic raised?
US Biologic has raised a total of $1.1M across 2 funding rounds:
Debt
$1M
Debt
$106K
Debt (2017): $1M, investors not publicly disclosed
Debt (2021): $106K led by PPP
Key Investors in US Biologic
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed institutional backer providing capital to support the long-term growth and operational scaling of the enterprise.
Undisclosed Investor
A financial entity specializing in debt-based capital structures to facilitate corporate expansion and research initiatives.
What's next for US Biologic?
With this major strategic investment, US Biologic is well-positioned to accelerate its operational roadmap and expand its research and development capabilities. The company is expected to prioritize the commercialization of its existing pipeline while scaling its manufacturing capacity to meet the growing demand for effective, non-invasive vaccine delivery. Future growth will likely be defined by strategic partnerships with healthcare providers and animal health organizations, aimed at integrating their oral delivery technology into standard disease management protocols. By maintaining a focus on high-impact public health outcomes, the firm is poised to solidify its market leadership and drive long-term value through continued innovation in the vaccine delivery space.
See full US Biologic company page
